Progress with palbociclib in breast cancer: latest evidence and clinical considerations
暂无分享,去创建一个
Andrea Rocca | Sara Bravaccini | G. Bronte | Giuseppe Bronte | Roberta Maltoni | A. Rocca | Daniele Andreis | Alberto Farolfi | Lorenzo Cecconetto | Alessio Schirone | S. Bravaccini | A. Farolfi | R. Maltoni | D. Andreis | A. Schirone | L. Cecconetto
[1] Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18 , 2016, Breast Cancer Research.
[2] P. Vogt. Cyclin Dependent Kinase , 2011 .
[3] R. Finn,et al. Impact of palbociclib plus letrozole on pain severity and pain interference with daily activities in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer as first-line treatment , 2016, Current medical research and opinion.
[4] J. LaBaer,et al. New functional activities for the p21 family of CDK inhibitors. , 1997, Genes & development.
[5] L. Butler,et al. Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors , 2012, Cell cycle.
[6] M. Pagano,et al. Regulation of the Cdk inhibitor p27 and its deregulation in cancer , 2000, Journal of cellular physiology.
[7] T. Shen,et al. The role of Cdc25A in the regulation of cell proliferation and apoptosis. , 2012, Anti-cancer agents in medicinal chemistry.
[8] N. Ueno,et al. Effects of CDK4/6 Inhibition in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Cells with Acquired Resistance to Paclitaxel , 2016, Journal of Cancer.
[9] A. D. Van den Abbeele,et al. Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. , 2012, Blood.
[10] H. Rui,et al. RB-pathway disruption in breast cancer , 2010, Cell cycle.
[11] Pierre Dubus,et al. Cdk1 is sufficient to drive the mammalian cell cycle , 2007, Nature.
[12] P. Robbins,et al. Differential regulation of E2F and Sp1-mediated transcription by G1 cyclins. , 1995, Oncogene.
[13] Ludger Hengst,et al. The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy , 2008, Nature Reviews Cancer.
[14] S. Conrad,et al. c-Myc Suppresses p21WAF1/CIP1 Expression during Estrogen Signaling and Antiestrogen Resistance in Human Breast Cancer Cells* , 2005, Journal of Biological Chemistry.
[15] R. Clarke,et al. Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer. , 2011, Endocrine-related cancer.
[16] F. Kaye,et al. Abstract 693: Inhibitory effect of the CDK4/6 inhibitor, PD 0332991, is enhanced by mTOR inhibition in Non-Small Cell Lung Cancer (NSCLC). , 2013 .
[17] Shih-Yin Tsai,et al. Emerging roles of E2Fs in cancer: an exit from cell cycle control , 2009, Nature Reviews Cancer.
[18] T. Burke,et al. The CDK4/6 Inhibitor LY2835219 Overcomes Vemurafenib Resistance Resulting from MAPK Reactivation and Cyclin D1 Upregulation , 2013, Molecular Cancer Therapeutics.
[19] N. Sharpless,et al. Forging a signature of in vivo senescence , 2015, Nature Reviews Cancer.
[20] A. Belldegrun,et al. PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity. , 2013, Anticancer research.
[21] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumors , 2012, Nature.
[22] Kathleen R. Cho,et al. Frequency of homozygous deletion at p16/CDKN2 in primary human tumours , 1995, Nature Genetics.
[23] Fang Liu,et al. Cyclin-dependent kinases regulate the antiproliferative function of Smads , 2004, Nature.
[24] H. Hirai,et al. Interaction of D-type cyclins with a novel myb-like transcription factor, DMP1 , 1996, Molecular and cellular biology.
[25] M. Scharfe,et al. Cyclin-dependent kinase 6 is a chromatin-bound cofactor for NF-κB-dependent gene expression. , 2014, Molecular cell.
[26] Shengjun Ren,et al. Cyclin C/Cdk3 Promotes Rb-Dependent G0 Exit , 2004, Cell.
[27] S. Fox,et al. Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines , 2014, Pigment cell & melanoma research.
[28] E. Knudsen,et al. Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure , 2010, Oncogene.
[29] J. Beijnen,et al. P-glycoprotein and breast cancer resistance protein restrict the brain penetration of the CDK4/6 inhibitor palbociclib , 2015, Investigational New Drugs.
[30] Sabrina L. Spencer,et al. The Proliferation-Quiescence Decision Is Controlled by a Bifurcation in CDK2 Activity at Mitotic Exit , 2013, Cell.
[31] X. Graña,et al. Proliferative suppression by CDK4/6 inhibition: complex function of the retinoblastoma pathway in liver tissue and hepatoma cells. , 2010, Gastroenterology.
[32] C. Perou,et al. Palbociclib--Taking Breast-Cancer Cells Out of Gear. , 2015, New England Journal of Medicine.
[33] R. Finn,et al. Phase I study of PD 0332991, cyclin-D kinase (CDK) 4/6 inhibitor in combination with letrozole for first-line treatment of patients with ER-positive, HER2-negative breast cancer. , 2010 .
[34] E. Andrechek. HER2/Neu tumorigenesis and metastasis is regulated by E2F activator transcription factors , 2013, Oncogene.
[35] P. Puigserver,et al. Cyclin D1-CDK4 Controls Glucose Metabolism Independently of Cell Cycle Progression , 2014, Nature.
[36] R. Schiff,et al. ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer , 2015, Nature Reviews Clinical Oncology.
[37] M. Barbacid,et al. Cell cycle, CDKs and cancer: a changing paradigm , 2009, Nature Reviews Cancer.
[38] Charles M. Perou,et al. Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy. , 2012, Journal of the National Cancer Institute.
[39] K. Suda,et al. G1 arrest and expression of cyclin-dependent kinase inhibitors in tamoxifen-treated MCF-7 human breast cancer cells , 2008, Human Cell.
[40] L. Skoog,et al. Cytoplasmic p21WAF1/CIP1 correlates with Akt activation and poor response to tamoxifen in breast cancer. , 2006, International journal of oncology.
[41] T. Ruhstaller,et al. Palbociclib as a first-line treatment in oestrogen receptor-positive, HER2-negative, advanced breast cancer not cost-effective with current pricing: a health economic analysis of the Swiss Group for Clinical Cancer Research (SAKK) , 2016, Breast Cancer Research and Treatment.
[42] Sarat Chandarlapaty,et al. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. , 2011, Cancer cell.
[43] M. Monden,et al. Antisense to Cyclin D1 Inhibits Vascular Endothelial Growth Factor–Stimulated Growth of Vascular Endothelial Cells: Implication of Tumor Vascularization , 2006, Clinical Cancer Research.
[44] G. Peters,et al. The p16INK4a/CDKN2A tumor suppressor and its relatives. , 1998, Biochimica et biophysica acta.
[45] G. Mills,et al. ERα-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer. , 2011, Cancer discovery.
[46] E. Winer,et al. Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors. , 2016, Cancer cell.
[47] R. Schiff,et al. The changing role of ER in endocrine resistance. , 2015, Breast.
[48] M. Beckmann,et al. Gene amplification and overexpression of CDK4 in sporadic breast carcinomas is associated with high tumor cell proliferation. , 1999, The American journal of pathology.
[49] S. Gygi,et al. A systematic screen for CDK4/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells. , 2011, Cancer cell.
[50] B. Jessen,et al. Mechanistic Investigation of Bone Marrow Suppression Associated with Palbociclib and its Differentiation from Cytotoxic Chemotherapies , 2015, Clinical Cancer Research.
[51] R. Bernards,et al. CDK-Independent Activation of Estrogen Receptor by Cyclin D1 , 1997, Cell.
[52] R. Finn,et al. Treating cancer with selective CDK4/6 inhibitors , 2016, Nature Reviews Clinical Oncology.
[53] M. Ellis,et al. Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy–Resistant Breast Cancer , 2015, Clinical Cancer Research.
[54] R. Finn,et al. Abstract 4756: In vivo efficacy of combined targeting of CDK4/6, ER and PI3K signaling in ER+ breast cancer , 2014 .
[55] K. Gelmon,et al. PALOMA-2: Primary results from a phase III trial of palbociclib (P) with letrozole (L) compared with letrozole alone in postmenopausal women with ER+/HER2– advanced breast cancer (ABC). , 2016 .
[56] R. Sutherland,et al. Expression of the cyclin‐dependent kinase inhibitors p16INK4, p15INK4B and p21Waf1/cip1 in human breast cancer , 1995, International journal of cancer.
[57] M. Herlyn,et al. Nuclear cyclin D1/CDK4 kinase regulates CUL4 expression and triggers neoplastic growth via activation of the PRMT5 methyltransferase. , 2010, Cancer cell.
[58] S. Rane,et al. Cyclin-dependent kinase 4 expression is essential for neu-induced breast tumorigenesis. , 2005, Cancer research.
[59] L. Rydén,et al. Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients , 2004, British Journal of Cancer.
[60] M. Malumbres,et al. Cyclin-dependent kinases , 2014, Genome Biology.
[61] J. Bartek,et al. Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. , 1994, Cancer research.
[62] James A. DeCaprio,et al. The DREAM complex: master coordinator of cell cycle-dependent gene expression , 2013, Nature Reviews Cancer.
[63] D. Hanahan,et al. Hallmarks of Cancer: The Next Generation , 2011, Cell.
[64] Zhaowu Ma,et al. Phylogenetic analysis reveals the evolution and diversification of cyclins in eukaryotes , 2013 .
[65] Y. Geng,et al. Specific protection against breast cancers by cyclin D1 ablation , 2001, Nature.
[66] H. Ditzel,et al. High CDK6 Protects Cells from Fulvestrant-Mediated Apoptosis and is a Predictor of Resistance to Fulvestrant in Estrogen Receptor–Positive Metastatic Breast Cancer , 2016, Clinical Cancer Research.
[67] R. Nicholson,et al. Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex). , 2001, Endocrinology.
[68] G. Mills,et al. Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. , 2010, The Journal of clinical investigation.
[69] S. Loi,et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. , 2016, The Lancet Oncology.
[70] G. Shapiro,et al. Clinical Development of the CDK4/6 Inhibitors Ribociclib and Abemaciclib in Breast Cancer , 2016, Breast Care.
[71] E. Mardis,et al. Abstract S6-05: A phase II trial of neoadjuvant palbociclib, a cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with anastrozole for clinical stage 2 or 3 estrogen receptor positive HER2 negative (ER+HER2-) breast cancer (BC) , 2016 .
[72] E. Knudsen,et al. Modification of the DNA Damage Response by Therapeutic CDK4/6 Inhibition , 2012, The Journal of Biological Chemistry.
[73] L. Montanaro,et al. High prevalence of retinoblastoma protein loss in triple-negative breast cancers and its association with a good prognosis in patients treated with adjuvant chemotherapy. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[74] M. Dowsett,et al. Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer. , 2016, Cancer research.
[75] Robert L. Sutherland,et al. Cyclin D as a therapeutic target in cancer , 2011, Nature Reviews Cancer.
[76] R. Nicholson,et al. Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. , 2003, Endocrinology.
[77] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumours , 2013 .
[78] M. Prados,et al. Inhibition of DNA damage repair by the CDK4/6 inhibitor palbociclib delays irradiated intracranial atypical teratoid rhabdoid tumor and glioblastoma xenograft regrowth. , 2016, Neuro-oncology.
[79] Charles M Perou,et al. The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas , 2008, Breast Cancer Research.
[80] M. Dowsett,et al. Palbociclib (PAL) in combination with fulvestrant (F) in pre-/peri-menopausal (PreM) women with metastatic breast cancer (MBC) and prior progression on endocrine therapy – results from Paloma-3. , 2016 .
[81] Wuguo Deng,et al. Palbociclib inhibits epithelial-mesenchymal transition and metastasis in breast cancer via c-Jun/COX-2 signaling pathway , 2015, Oncotarget.
[82] Michael Ruogu Zhang,et al. Dissecting the Unique Role of the Retinoblastoma Tumor Suppressor during Cellular Senescence , 2022 .
[83] D. D. Wang,et al. 462PA POPULATION PHARMACOKINETIC (PK) ANALYSIS OF PALBOCICLIB (PD-0332991) IN PATIENTS (PTS) WITH ADVANCED SOLID TUMORS. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[84] O. Jänne,et al. Cyclin D1 binds the androgen receptor and regulates hormone-dependent signaling in a p300/CBP-associated factor (P/CAF)-dependent manner. , 2001, Molecular endocrinology.
[85] Y. Kotake,et al. pRB family proteins are required for H3K27 trimethylation and Polycomb repression complexes binding to and silencing p16INK4alpha tumor suppressor gene. , 2007, Genes & development.
[86] Clifford A. Meyer,et al. Transcriptional role of cyclin D1 in development revealed by a genetic–proteomic screen , 2010, Nature.
[87] Tiansen Li,et al. Cyclin D1-dependent kinase activity in murine development and mammary tumorigenesis. , 2006, Cancer cell.
[88] N. Pryer,et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. , 2004, Molecular cancer therapeutics.
[89] Antonin Bukovsky,et al. Multifaceted Regulation of Cell Cycle Progression by Estrogen: Regulation of Cdk Inhibitors and Cdc25A Independent of Cyclin D1-Cdk4 Function , 2001, Molecular and Cellular Biology.
[90] Jiri Bartek,et al. Cyclin D1 protein expression and function in human breast cancer , 1994, International journal of cancer.
[91] R. Bernards,et al. Targeting the RB-E2F pathway in breast cancer , 2016, Oncogene.
[92] M. Dowsett,et al. Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[93] A. Mercurio,et al. Ras stimulation of E2F activity and a consequent E2F regulation of integrin alpha6beta4 promote the invasion of breast carcinoma cells. , 2006, Cancer research.
[94] J. Hoffman,et al. Physiologically Based Pharmacokinetic Modeling of Palbociclib , 2017, Journal of clinical pharmacology.
[95] T. Shibata,et al. Induction of ZEB Proteins by Inactivation of RB Protein Is Key Determinant of Mesenchymal Phenotype of Breast Cancer* , 2012, Journal of Biological Chemistry.
[96] Xin Huang,et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. , 2015, The Lancet. Oncology.
[97] K. Wilner,et al. Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1) , 2011, British Journal of Cancer.
[98] P. Argani,et al. Most Basal-like Breast Carcinomas Demonstrate the Same Rb−/p16+ Immunophenotype as the HPV-related Poorly Differentiated Squamous Cell Carcinomas Which They Resemble Morphologically , 2009, The American journal of surgical pathology.
[99] U. Asghar,et al. Identification of subtypes of triple negative breast cancer (TNBC) that are sensitive to CDK4/6 inhibition. , 2015 .
[100] J. Carroll,et al. Constitutive overexpression of cyclin D1 but not cyclin E confers acute resistance to antiestrogens in T-47D breast cancer cells. , 2002, Cancer research.
[101] J. Sage. The retinoblastoma tumor suppressor and stem cell biology. , 2012, Genes & development.
[102] H. Rui,et al. Cyclin D3 compensates for the loss of cyclin D1 during ErbB2-induced mammary tumor initiation and progression. , 2011, Cancer research.
[103] L. Altucci,et al. 17beta-Estradiol induces cyclin D1 gene transcription, p36D1-p34cdk4 complex activation and p105Rb phosphorylation during mitogenic stimulation of G(1)-arrested human breast cancer cells. , 1996, Oncogene.
[104] Frederick A. Dick,et al. Molecular mechanisms underlying RB protein function , 2013, Nature Reviews Molecular Cell Biology.
[105] A. Mercurio,et al. Ras stimulation of E2F activity and a consequent E2F regulation of integrin alpha6beta4 promote the invasion of breast carcinoma cells. , 2006, Cancer research.
[106] R. Weinberg,et al. The retinoblastoma protein and cell cycle control , 1995, Cell.
[107] Anne-Marie Duchemin,et al. Pharmacologic inhibition of CDK4/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia. , 2007, Blood.
[108] I. Bièche,et al. Abstract CT041: Anti-proliferative response and predictive biomarkers to palbociclib in early breast cancer: The Preoperative Palbociclib (POP) randomized trial , 2016 .
[109] Yan Geng,et al. Requirement for CDK4 kinase function in breast cancer. , 2006, Cancer cell.
[110] J. Lehár,et al. CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors. , 2014, Cancer cell.
[111] S. Loi,et al. Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[112] James M. Roberts,et al. CDK inhibitors: positive and negative regulators of G1-phase progression. , 1999, Genes & development.
[113] S. Loi,et al. Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. , 2015, The New England journal of medicine.
[114] Tuan S. Nguyen,et al. Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors. , 2016, Cancer discovery.
[115] J. Harbour,et al. Cdk Phosphorylation Triggers Sequential Intramolecular Interactions that Progressively Block Rb Functions as Cells Move through G1 , 1999, Cell.
[116] G. Mills,et al. Loss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer. , 2009, Cancer research.
[117] A. Bardia,et al. Abstract P6-13-01: Triplet therapy with ribociclib, everolimus, and exemestane in women with HR+/HER2– advanced breast cancer , 2016 .
[118] Pierre Dubus,et al. Mammalian Cells Cycle without the D-Type Cyclin-Dependent Kinases Cdk4 and Cdk6 , 2004, Cell.
[119] S. Loi,et al. Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3). , 2016, The oncologist.
[120] A. Look,et al. The requirement for cyclin D function in tumor maintenance. , 2012, Cancer cell.
[121] E. Reddy,et al. Increased angiogenesis in Cdk4R24C/R24C:Apc+/Min intestinal tumors , 2010, Cell cycle.
[122] Retinoblastoma tumor suppressor pathway in breast cancer: prognosis, precision medicine, and therapeutic interventions , 2014, Breast Cancer Research.
[123] Yonghong Xiao,et al. Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM , 2010, Proceedings of the National Academy of Sciences.
[124] Robert A. Weinberg,et al. Functional Inactivation of the Retinoblastoma Protein Requires Sequential Modification by at Least Two Distinct Cyclin-cdk Complexes , 1998, Molecular and Cellular Biology.
[125] V. Velculescu,et al. Expression of p16 and Retinoblastoma Determines Response to CDK4/6 Inhibition in Ovarian Cancer , 2011, Clinical Cancer Research.
[126] J. Dering,et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro , 2009, Breast Cancer Research.
[127] K. Flaherty,et al. Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer , 2011, Clinical Cancer Research.
[128] Joshua E. Elias,et al. A function for cyclin D1 in DNA repair uncovered by protein interactome analyses in human cancers , 2011, Nature.
[129] D. Heitjan,et al. CDK 4/6 Inhibitor Palbociclib (PD0332991) in Rb+ Advanced Breast Cancer: Phase II Activity, Safety, and Predictive Biomarker Assessment , 2014, Clinical Cancer Research.
[130] S. Lowe,et al. The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer. , 2007, The Journal of clinical investigation.
[131] Ananda Sen,et al. Sensitivity of KRAS-Mutant Colorectal Cancers to Combination Therapy That Cotargets MEK and CDK4/6 , 2015, Clinical Cancer Research.
[132] M. Malumbres,et al. A Kinase-Independent Function of CDK6 Links the Cell Cycle to Tumor Angiogenesis , 2013, Cancer cell.
[133] M. Malumbres,et al. Non-canonical functions of cell cycle cyclins and cyclin-dependent kinases , 2016, Nature Reviews Molecular Cell Biology.
[134] J. Carroll,et al. A Pure Estrogen Antagonist Inhibits Cyclin E-Cdk2 Activity in MCF-7 Breast Cancer Cells and Induces Accumulation of p130-E2F4 Complexes Characteristic of Quiescence* , 2000, The Journal of Biological Chemistry.
[135] Hui Zhang,et al. D type cyclins associate with multiple protein kinases and the DNA replication and repair factor PCNA , 1992, Cell.
[136] James M. Roberts,et al. p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. , 1994, Genes & development.
[137] W. Koch,et al. CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy , 2012, Cell cycle.
[138] A. Iavarone,et al. Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta. , 1995, Genes & development.